Age Range
18+
Trial Purpose
Umgomo walolu cwaningo ukuhlola i-nemtabrutinib uma kuqhathaniswa nokukhetha komseshi kwe-ibrutinib noma i-acalabrutinib kubahlanganyeli abane-lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) abangazange bathole noma yikuphi ukwelashwa kwangaphambili. Ama-hypotheses ayinhloko ukuthi (1) i-nemtabrutinib ayikho ngaphansi kwe-ibrutinib noma i-acalabrutinib ngokuphathelene nezinga lokuphendula lenjongo (ORR) nge-International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) kanye (2) nemtabrutinion i-ibrutinib ekhululekile noma i-ibrutinib ekhululekile ukusinda (PFS) ngokwemibandela ye-iwCLL 2018 yi-BICR.
NATIONAL TRIAL REFERENCE NUMBER
I-NCT06136559
EU CT Number
2022-501697-19-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
About The Study
Zonke iziguli ezibhalisela ukuhlola zizothola imithi ngenkathi usocwaningweni.
U-50% uzothola i-nemtabrutinib
I-50% izothola i-ibrutinib noma i-acalabrutinib
Trial Phase
Trial start and end dates
- Actual study start date Disemba 13, 2023
- Estimated primary completion date Septhemba 30, 2032
- Estimated study completion date Septhemba 30, 2032